Airway　inflammation　is　the　major　pathological　feature　of　asthma.　Thus,　the　current　therapeutic　strategy　for　asthma　is　to　control　inflammation.　Limethason,　an　anti-inflammation　drug,　is　widely　used　in　rheumatoid　arthritis　treatment.　The　aim　of　the　present　study　was　to　detect　the　anti-inflammatory　effect　and　side　effects　of　limethason　on　airways　that　were　sensitized　with　ovalbumin　in　a　murine　model　of　chronic　asthma.　In　the　present　study,　BALB/c　mice　were　sensitized　with　ovalbumin.　Airway　hyperresponsiveness　was　estimated,　and　hematoxylin　and　eosin　staining,　Periodic　acid-Schiff　staining　and　bronchoalveolar　lavage　were　used　to　detect　the　effect　on　chronic　asthma.　Limethason　effectively　reduced　airway　hyperresponsiveness,　and　inhibited　inflammatory　cell　infiltration　and　mucus　secretion.　Bronchoalveolar　lavage　fluid　analysis　revealed　that　limethason　suppressed　levels　of　airway　eosinophils.　In　the　period　of　treatment,　limethason　exhibited　no　influence　on　morphology　of　the　femoral　head,　bone　mineral　content　or　bone　mineral　density,　which　were　detected　by　histological　studies　and　dual-energy　X-ray　absorptiometry.　The　index　of　liver,　spleen,　kidney,　gastrocnemius　and　brown　adipose　tissue　also　demonstrated　that　limethason　had　no　adverse　effects　on　organs　and　tissues.　The　present　study　revealed　that　limethason　could　effectively　reduce　inflammation　in　an　asthma　mouse　model　without　side　effects.　Therefore,　limethason　may　have　therapeutic　potential　for　treating　chronic　asthma　clinically.